Abstract 1511P
Background
Gemcitabine-based adjuvant chemotherapy (aGC) is a therapeutic mainstay after surgery for pancreatic ductal adenocarcinoma (PDAC), but relevant efficacy predictors are still lacking. Intratumoral gram-negative bacteria can suppress response to aGC. We assessed the effect of intratumoral bacterial colonization on aGC-efficacy and examined whether peri-operative antibiotic treatment (ABT) improved patient outcome.
Methods
Intratumoral bacteria were detected by immunohistochemistry (IHC) for lipopolysaccharide (gram-negative) and lipoteichoic acid (gram-positive) in the samples of 342 resected PDAC patients treated with either aGC or none / non-gemcitabine-based adjuvant chemotherapy (naGC). Preoperative ABT was defined as ABT for more than 24 hours within 30 days before resection. Postoperative ABT was defined as ABT for more than 24 hours within 30 days after resection. Data of 177 patients from the TCGA database were used for validation.
Results
High bacterial colonization (bacHI) conferred worse disease-free survival (DFS, 9.4 vs 19.1 months, p<0.001) and overall survival (OS, 19.4 months vs 34.0 months, p<0.001) in aGC patients, but made no statistical difference in naGC patients (p=0.66 and p=0.42). BacHI did not correlate with the tumors transcriptional subtype, pre-operative ATB, bile duct interventions or other prognostic clinicopathological variables. Pre-operative ABT did not affect patient outcome, irrespective of adjuvant chemotherapy. Post-operative ABT significantly improved patientś DFS (17.5 vs. 10.8 months, p<0.001) and OS (37.8 vs. 20.6 months, p<0.001) in the aGC cohort, but not in the naGC cohort (p=0.60 and p=0.97). The findings were confirmed by inverse propensity score weighted multivariable Cox regression analyses and in the external validation cohort.
Conclusions
High intratumoral bacterial abundance is a negative predictor of adjuvant gemcitabine efficacy in PDAC but can be overcome by post-operative antibiotic treatment prior adjuvant therapy. Detection of intratumoral bacteria in resection specimens by IHC may guide the use of antibiotics to improve therapy response and patient outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1455P - Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastroesophageal junction cancer: A prospective, single-arm, phase II clinical trial
Presenter: Pengfei Zhang
Session: Poster session 18
Resources:
Abstract
1456P - First in human phase I/II trial of claudin 18.2 ADC RC118 in patients with advanced gastric/gastroesophageal junction cancer
Presenter: Tianshu Liu
Session: Poster session 18
1457P - Tumor immune microenvironment subtypes of esophageal squamous cell carcinoma and their strong ability to predict the efficacy of neoadjuvant immunotherapy
Presenter: Guangyu Yao
Session: Poster session 18
1458P - Impact of 68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) on staging and treatment in patients with gastric cancer
Presenter: Shunyu Zhang
Session: Poster session 18
Resources:
Abstract
1459P - Long-term management and outcomes in gastroesophageal cancer in Norway
Presenter: Aleksander Kolstad
Session: Poster session 18
1460P - Association between effectiveness of treatment with curative intent and outcomes of first-line systemic therapy in metachronous metastatic esophagogastric cancer
Presenter: Denice Kamp
Session: Poster session 18
1462P - A pilot study of hypoxia as a potential resistance mechanism to PD-1 checkpoint blockade therapy in neoadjuvant treatment of esophageal squamous cell carcinoma (HYPERION)
Presenter: Bin Li
Session: Poster session 18
1463P - The presence of liver metastases is associated with systemic immune suppression in gastroesophageal cancer
Presenter: Sebastiaan Siegerink
Session: Poster session 18
1464P - Chemo-radiation alone associated with higher risk of death compared to chemo-radiation plus surgery in esophageal squamous cell carcinoma
Presenter: Brian Housman
Session: Poster session 18